{
    "clinical_study": {
        "@rank": "1573", 
        "acronym": "CRIB", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Ecologic 825/scFOS", 
                "arm_group_type": "Experimental", 
                "description": "Ecologic 825/scFOS"
            }
        ], 
        "brief_summary": {
            "textblock": "In the present pilot study, the investigators will study the effects of a novel synbiotic,\n      which is a mix of probiotics (Ecologic 825) in the presence of a prebiotic (short chain\n      fructo-oligosaccharide (scFOS)), on mucosal integrity, overall microbiota changes along the\n      gastrointestinal-tract and the mucosal immune response. The investigators hypothesize that\n      the synbiotic Ecologic 825/scFOS will significantly affect the intestinal permeability and\n      modulate the immune system in humans."
        }, 
        "brief_title": "The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function and Immune Modulation", 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Based on medical history and previous self-admitted examination, no gastrointestinal\n             complaints can be defined\n\n          -  Age between 18 and 65 years\n\n          -  Body Mass Index (BMI) between 20 and 30 kilogram/m2\n\n        Exclusion Criteria:\n\n          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,\n             hematological/immunologic, head, ears, eyes, nose, throat (HEENT),\n             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,\n             neurological diseases, allergy, major surgery and/or laboratory assessments which\n             might limit participation in or completion of the study protocol.  - Use of\n             medication, including vitamin supplementation, except oral contraceptives, within 14\n             days prior to testing\n\n          -  Administration of probiotic supplements, investigational drugs or participation in\n             any scientific intervention study which may interfere with this study (to be decided\n             by the principle investigator), in the 180 days prior to the study\n\n          -  Use of antibiotics in the 90 days prior to the study\n\n          -  Abdominal surgery interfering with gastrointestinal function, upon judgment of the\n             principle investigator)\n\n          -  Pregnancy, lactation\n\n          -  Excessive alcohol consumption (>20 alcoholic consumptions per week)\n\n          -  Smoking\n\n          -  Blood donation within 3 months before or after the study period\n\n          -  Self-admitted Human immunodeficiency virus-positive state\n\n          -  History of any side effects towards intake of pro- or prebiotic supplements of any\n             kind"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018900", 
            "org_study_id": "13-3-016"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ecologic 825/scFOS", 
                "intervention_name": "Ecologic 825/scFOS", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Synbiotics", 
            "Intestinal permeability", 
            "Microbiota", 
            "Immune response"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "contact": {
                "email": "e.wilms@maastrichtuniversity.nl", 
                "last_name": "Ellen Wilms, MSc", 
                "phone": "0031433884295"
            }, 
            "facility": {
                "address": {
                    "city": "Maastricht", 
                    "country": "Netherlands", 
                    "state": "Limburg", 
                    "zip": "6229 HX"
                }, 
                "name": "Maastricht University Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function", 
        "overall_contact": {
            "email": "e.wilms@maastrichtuniversity.nl", 
            "last_name": "Ellen Wilms, MSc", 
            "phone": "0031433884295"
        }, 
        "overall_official": {
            "affiliation": "Department of Internal Medicine, Division of Gastroenterology-Hepatology", 
            "last_name": "A.A.M. Masclee, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sugar recovery in urine, as indicator of intestinal permeability", 
            "safety_issue": "No", 
            "time_frame": "Baseline and after 2 weeks intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018900"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Biomarkers of immune modulation; plasma levels of Tumor necrosis factor alpha , Interleukin-1 beta, Interleukin-6, Interleukin-8, Interleukin-17, Monocyte chemoattractant protein-1 and Macrophage inflammatory protein-1a", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }, 
            {
                "measure": "Relative abundance of commensal rat ileum bacterium (CRIB) by quantitative polymerase chain reaction (qPCR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }, 
            {
                "measure": "Barcoded pyrosequencing of 16S rRNA genes of the microbiota", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }, 
            {
                "measure": "Metatranscriptomics of the microbiota", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }, 
            {
                "measure": "10 item gastrointestinal symptom diary", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }, 
            {
                "measure": "Quantitative Insights Into Microbial Ecology (QIIME) of the microbiota", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 2 weeks intervention"
            }
        ], 
        "source": "Maastricht University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maastricht University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}